Paula Green Sells 282 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green sold 282 shares of the firm’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $44.90, for a total value of $12,661.80. Following the transaction, the senior vice president now directly owns 133,433 shares in the company, valued at $5,991,141.70. This trade represents a 0.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

Paula Green also recently made the following trade(s):

• On Friday, December 6th, Paula Green sold 860 shares of Twist Bioscience stock. The shares were sold at an average price of $52.70, for a total transaction of $45,322.00.
• On Monday, November 11th, Paula Green sold 1,347 shares of Twist Bioscience stock. The stock was sold at an average price of $48.00, for a total transaction of $64,656.00.
• On Wednesday, November 6th, Paula Green sold 5,519 shares of Twist Bioscience stock. The shares were sold at an average price of $44.60, for a total transaction of $246,147.40.
• On Monday, November 4th, Paula Green sold 1,057 shares of Twist Bioscience stock. The stock was sold at an average price of $41.56, for a total value of $43,928.92.
• On Wednesday, October 2nd, Paula Green sold 3,310 shares of Twist Bioscience stock. The shares were sold at an average price of $43.21, for a total value of $143,025.10.

Twist Bioscience Price Performance

Twist Bioscience stock opened at $48.17 on Friday. Twist Bioscience Co. has a fifty-two week low of $27.41 and a fifty-two week high of $60.90. The firm’s 50 day simple moving average is $45.61 and its 200-day simple moving average is $46.72. The company has a market cap of $2.86 billion, a P/E ratio of -13.38 and a beta of 1.82.

Hedge Funds Weigh In On Twist Bioscience

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Caprock Group LLC lifted its holdings in shares of Twist Bioscience by 2.9% in the second quarter. Caprock Group LLC now owns 7,851 shares of the company’s stock valued at $387,000 after purchasing an additional 220 shares in the last quarter. Signaturefd LLC raised its position in Twist Bioscience by 63.0% during the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after buying an additional 306 shares during the period. Arizona State Retirement System lifted its stake in Twist Bioscience by 1.9% in the 2nd quarter. Arizona State Retirement System now owns 16,187 shares of the company’s stock worth $798,000 after acquiring an additional 308 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its position in Twist Bioscience by 3.5% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 9,279 shares of the company’s stock worth $457,000 after acquiring an additional 312 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Twist Bioscience by 2.3% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,243 shares of the company’s stock valued at $734,000 after acquiring an additional 363 shares in the last quarter.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. Wolfe Research started coverage on Twist Bioscience in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective for the company. Scotiabank upped their price target on shares of Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a report on Tuesday, November 19th. Evercore ISI lifted their price objective on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Leerink Partners increased their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. Finally, TD Cowen restated a “buy” rating and set a $58.00 target price on shares of Twist Bioscience in a report on Tuesday, November 26th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, Twist Bioscience presently has an average rating of “Moderate Buy” and a consensus price target of $51.90.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.